[
  {
    "ts": null,
    "headline": "Fidelity Contrafund Q4 2024 Review",
    "summary": "For Q4 2024, the Fidelity Contrafund's Retail Class shares gained 3.56%, topping the 2.41% advance of the S&P 500Â® index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=3a0a5a73483fa9fd7e332d0b4cf17231696a722fb5cfb954e54a0be6eb6011ff",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738794900,
      "headline": "Fidelity Contrafund Q4 2024 Review",
      "id": 132569795,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/952762622/image_952762622.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "For Q4 2024, the Fidelity Contrafund's Retail Class shares gained 3.56%, topping the 2.41% advance of the S&P 500Â® index. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=3a0a5a73483fa9fd7e332d0b4cf17231696a722fb5cfb954e54a0be6eb6011ff"
    }
  },
  {
    "ts": null,
    "headline": "REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit",
    "summary": "NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. between November 2, 2023 and October 30,...",
    "url": "https://finnhub.io/api/news?id=e2fe81ab7a935cef430f9a3c7a3fd6b2387e1a95ea85575d8561d3ea952696fe",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738780985,
      "headline": "REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit",
      "id": 132568884,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. between November 2, 2023 and October 30,...",
      "url": "https://finnhub.io/api/news?id=e2fe81ab7a935cef430f9a3c7a3fd6b2387e1a95ea85575d8561d3ea952696fe"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval",
    "summary": "REGN and AMGN are in the spotlight this week on fourth-quarter earnings release.",
    "url": "https://finnhub.io/api/news?id=d2ff6b9a20204a5e2c275a0de09a1e4c1bb5f32a4c807d155d5bf57456f03b0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738774020,
      "headline": "Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval",
      "id": 132601926,
      "image": "https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN and AMGN are in the spotlight this week on fourth-quarter earnings release.",
      "url": "https://finnhub.io/api/news?id=d2ff6b9a20204a5e2c275a0de09a1e4c1bb5f32a4c807d155d5bf57456f03b0f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=8390e5db24a24d944e92c4c7bb55fc1f778c797f1f1e91a5c96ef946bba97ac3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738773720,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
      "id": 132579350,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=8390e5db24a24d944e92c4c7bb55fc1f778c797f1f1e91a5c96ef946bba97ac3"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Is Playing Defense With Capital Allocation",
    "summary": "Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read why I rate REGN a Buy.",
    "url": "https://finnhub.io/api/news?id=9a0c9b25731d76b789ce893a51dade7a12e0b641dc763a1ebb21f152d7bed54c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738761030,
      "headline": "Regeneron Is Playing Defense With Capital Allocation",
      "id": 132563616,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2129856936/image_2129856936.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read why I rate REGN a Buy.",
      "url": "https://finnhub.io/api/news?id=9a0c9b25731d76b789ce893a51dade7a12e0b641dc763a1ebb21f152d7bed54c"
    }
  },
  {
    "ts": null,
    "headline": "Amgen obesity drug on hold; Regeneron sets first dividend",
    "summary": "Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.”",
    "url": "https://finnhub.io/api/news?id=31f9129bfee32c4aad47fee283251380f8439f1b64f7d6fb163433405683aba9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738754880,
      "headline": "Amgen obesity drug on hold; Regeneron sets first dividend",
      "id": 132601927,
      "image": "https://imgproxy.divecdn.com/EK5xKj0ydykvmwFmBqsauREtdhrHAUsAiyI6JgDkO1s/g:nowe:0:0/c:1207:682/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDgzOTIxNzkzLmpwZw==.webp",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.”",
      "url": "https://finnhub.io/api/news?id=31f9129bfee32c4aad47fee283251380f8439f1b64f7d6fb163433405683aba9"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations",
    "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN ) Full Year 2024 Results Key Financial Results Revenue: US$14.2b (up 8.3% from...",
    "url": "https://finnhub.io/api/news?id=48ee5500c238b39e29f999b2f94b6bbd195976602016b64a05569cc05fbf5edb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738754836,
      "headline": "Regeneron Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations",
      "id": 132601928,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals ( NASDAQ:REGN ) Full Year 2024 Results Key Financial Results Revenue: US$14.2b (up 8.3% from...",
      "url": "https://finnhub.io/api/news?id=48ee5500c238b39e29f999b2f94b6bbd195976602016b64a05569cc05fbf5edb"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Feb 5, 2025",
    "summary": "Companies In The News Are: RACE, REGN, MPLX, WEC.",
    "url": "https://finnhub.io/api/news?id=fb3aea79dae66df957866bfac77960955679ead5e61c3125701486ae802d21b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738752060,
      "headline": "Company News for Feb 5, 2025",
      "id": 132601929,
      "image": "https://media.zenfs.com/en/zacks.com/7c4df663699c823ba05ae4b84ac121f2",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Companies In The News Are: RACE, REGN, MPLX, WEC.",
      "url": "https://finnhub.io/api/news?id=fb3aea79dae66df957866bfac77960955679ead5e61c3125701486ae802d21b5"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Blue Chip Growth Fund Q4 2024 Commentary",
    "summary": "For Q4 2024, the Fidelity Blue Chip Growth Fund's Retail Class shares gained 9.12%, handily outpacing the benchmark. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=3fe7acc1f518c5b79647875f00651e8380ca832b0db7920c13dff2215f8c56ae",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738746600,
      "headline": "Fidelity Blue Chip Growth Fund Q4 2024 Commentary",
      "id": 132562503,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397047877/image_1397047877.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "For Q4 2024, the Fidelity Blue Chip Growth Fund's Retail Class shares gained 9.12%, handily outpacing the benchmark. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=3fe7acc1f518c5b79647875f00651e8380ca832b0db7920c13dff2215f8c56ae"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings",
    "summary": "Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for LIBTAYO in 2024. Read more here.",
    "url": "https://finnhub.io/api/news?id=6d053d8b0c2de44e8e9fd79d0e6f7e54589c26a8066a4091d94f87302426f94f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738741500,
      "headline": "Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings",
      "id": 132561931,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962536/image_1386962536.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for LIBTAYO in 2024. Read more here.",
      "url": "https://finnhub.io/api/news?id=6d053d8b0c2de44e8e9fd79d0e6f7e54589c26a8066a4091d94f87302426f94f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc (REGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...",
    "summary": "Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new strategic moves including dividend initiation and share repurchase authorization.",
    "url": "https://finnhub.io/api/news?id=47161f76119e89e50c9cc3ac8a563c97505926d2040ea45456dc84e94a7b4abc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738739237,
      "headline": "Regeneron Pharmaceuticals Inc (REGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...",
      "id": 132601930,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/c93aacc12a21c50f59b9851494e471ec",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new strategic moves including dividend initiation and share repurchase authorization.",
      "url": "https://finnhub.io/api/news?id=47161f76119e89e50c9cc3ac8a563c97505926d2040ea45456dc84e94a7b4abc"
    }
  },
  {
    "ts": null,
    "headline": "Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call",
    "summary": "Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call",
    "url": "https://finnhub.io/api/news?id=a0e8c569d8a2072081d885107302b95b2db900ac5c9729a7d07d8ce399bd88dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738736721,
      "headline": "Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call",
      "id": 132601931,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call",
      "url": "https://finnhub.io/api/news?id=a0e8c569d8a2072081d885107302b95b2db900ac5c9729a7d07d8ce399bd88dc"
    }
  }
]